The Investigation and Treatment of Diabetic Gastroparesis

Mohit Kumar, Adam Chapman, Saad Javed, Uazman Alam, Rayaz Malik, Shazli Azmi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: This review provides an update on the investigations and treatment options for gastroparesis. Methods: A comprehensive literature search of Medline, PubMed, Embase and OVID was conducted which included all systematic reviews and research articles that focused on the diagnosis, investigations and management diabetic gastroparesis. Findings: Dietary modifications and pharmacologic treatment with prokinetics to increase gastric motility form the mainstay of treatment. However, the use of prokinetics is limited by adverse effects and serious adverse effects, leaving metoclopramide as the only drug approved by the US Food and Drug Administration for the treatment of gastroparesis. Newer therapies, including motilin receptor agonists, ghrelin receptor agonists, and neurokinin receptor antagonists, are currently being investigated. Transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy provide mechanical options for intervention, and surgical interventions in severe intractable gastroparesis include laparoscopic pyloroplasty or gastrectomy. Implications: Advances to better understand the pathophysiology and management of diabetic gastroparesis have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise.

Original languageEnglish
JournalClinical Therapeutics
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Gastroparesis
Stomach
Therapeutics
Ghrelin Receptor
Diet Therapy
Metoclopramide
Gastric Emptying
United States Food and Drug Administration
Gastrectomy
PubMed
Electric Stimulation
Research
Pharmaceutical Preparations

Keywords

  • Gastroparesis
  • Microvascular
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The Investigation and Treatment of Diabetic Gastroparesis. / Kumar, Mohit; Chapman, Adam; Javed, Saad; Alam, Uazman; Malik, Rayaz; Azmi, Shazli.

In: Clinical Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Kumar, Mohit ; Chapman, Adam ; Javed, Saad ; Alam, Uazman ; Malik, Rayaz ; Azmi, Shazli. / The Investigation and Treatment of Diabetic Gastroparesis. In: Clinical Therapeutics. 2018.
@article{dcc82de7a1e346308759f5b335a4b4a2,
title = "The Investigation and Treatment of Diabetic Gastroparesis",
abstract = "Purpose: This review provides an update on the investigations and treatment options for gastroparesis. Methods: A comprehensive literature search of Medline, PubMed, Embase and OVID was conducted which included all systematic reviews and research articles that focused on the diagnosis, investigations and management diabetic gastroparesis. Findings: Dietary modifications and pharmacologic treatment with prokinetics to increase gastric motility form the mainstay of treatment. However, the use of prokinetics is limited by adverse effects and serious adverse effects, leaving metoclopramide as the only drug approved by the US Food and Drug Administration for the treatment of gastroparesis. Newer therapies, including motilin receptor agonists, ghrelin receptor agonists, and neurokinin receptor antagonists, are currently being investigated. Transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy provide mechanical options for intervention, and surgical interventions in severe intractable gastroparesis include laparoscopic pyloroplasty or gastrectomy. Implications: Advances to better understand the pathophysiology and management of diabetic gastroparesis have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise.",
keywords = "Gastroparesis, Microvascular, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus",
author = "Mohit Kumar and Adam Chapman and Saad Javed and Uazman Alam and Rayaz Malik and Shazli Azmi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clinthera.2018.04.012",
language = "English",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",

}

TY - JOUR

T1 - The Investigation and Treatment of Diabetic Gastroparesis

AU - Kumar, Mohit

AU - Chapman, Adam

AU - Javed, Saad

AU - Alam, Uazman

AU - Malik, Rayaz

AU - Azmi, Shazli

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: This review provides an update on the investigations and treatment options for gastroparesis. Methods: A comprehensive literature search of Medline, PubMed, Embase and OVID was conducted which included all systematic reviews and research articles that focused on the diagnosis, investigations and management diabetic gastroparesis. Findings: Dietary modifications and pharmacologic treatment with prokinetics to increase gastric motility form the mainstay of treatment. However, the use of prokinetics is limited by adverse effects and serious adverse effects, leaving metoclopramide as the only drug approved by the US Food and Drug Administration for the treatment of gastroparesis. Newer therapies, including motilin receptor agonists, ghrelin receptor agonists, and neurokinin receptor antagonists, are currently being investigated. Transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy provide mechanical options for intervention, and surgical interventions in severe intractable gastroparesis include laparoscopic pyloroplasty or gastrectomy. Implications: Advances to better understand the pathophysiology and management of diabetic gastroparesis have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise.

AB - Purpose: This review provides an update on the investigations and treatment options for gastroparesis. Methods: A comprehensive literature search of Medline, PubMed, Embase and OVID was conducted which included all systematic reviews and research articles that focused on the diagnosis, investigations and management diabetic gastroparesis. Findings: Dietary modifications and pharmacologic treatment with prokinetics to increase gastric motility form the mainstay of treatment. However, the use of prokinetics is limited by adverse effects and serious adverse effects, leaving metoclopramide as the only drug approved by the US Food and Drug Administration for the treatment of gastroparesis. Newer therapies, including motilin receptor agonists, ghrelin receptor agonists, and neurokinin receptor antagonists, are currently being investigated. Transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy provide mechanical options for intervention, and surgical interventions in severe intractable gastroparesis include laparoscopic pyloroplasty or gastrectomy. Implications: Advances to better understand the pathophysiology and management of diabetic gastroparesis have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise.

KW - Gastroparesis

KW - Microvascular

KW - Type 1 Diabetes Mellitus

KW - Type 2 Diabetes Mellitus

UR - http://www.scopus.com/inward/record.url?scp=85046632375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046632375&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2018.04.012

DO - 10.1016/j.clinthera.2018.04.012

M3 - Article

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

ER -